Intrastromal Injection of Fluconazole in Treatment of Fungal Keratitis

Tanta University40 enrolled

Overview

This study aimed to evaluate the Safety and the Effectiveness of Intrastromal Injection of Fluconazole in The Treatment of Fungal Keratitis.

Fungal keratitis is one of the most challenging types of infectious keratitis. It now accounts for approximately 50% of infectious corneal diseases, and corneal blindness has become the second leading cause of blindness in developing countries. The potentially poor prognosis may be due to a delay in diagnosis and / or to limited effective antifungal agents that leads to decrease visual acuity and blindness. Fluconazole is mainly a fungistatic drug with broad spectrum activity as it is effective against Yeast \& Dermatophytes (Candida, Cryptococcus neoformans \& Aspergillus species) Fluconazole is stable and a water-soluble small molecule with high bioavailability and low toxicity.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Safety Efficacy Intrastromal Injection Fluconazole Treatment Fungal Keratitis

Interventions

Topical fluconazole eye dropsDRUG

Eyes that received treatment as topical fluconazole eye drops

Intrastromal injection of fluconazoleDRUG

Eyes that received treatment as intrastromal injection of fluconazole.

Eligibility

Sex: ALLMin age: 30 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed both clinically and laboratory as fungal keratitis. * Fungal cultures should be sensitive to fluconazole. Exclusion Criteria: * Thin cornea. * Decmatocele. * Necrotic or perforated corneal ulcers. * Other types of keratitis (bacterial or viral). * Fungal cultures resistant to fluconazole. * Patients on immune-suppressants drugs. * Silicon oil filled eyes. * Previous ocular surgery e.g keratoplasty.

Locations (1)

Tanta University

Tanta, El-Gharbia, Egypt

Outcomes

Primary Outcomes

Best-corrected visual acuity

Best-corrected visual acuity (BCVA) was recorded and described by LogMAR notation.

Time frame: Every three days until complete healing (Up to 6 weeks)

Secondary Outcomes

Uncorrected visual acuity

Uncorrected visual acuity was recorded and described by LogMAR notation.

Time frame: Every three days until complete healing (Up to 6 weeks)

Duration of healing

Duration of healing was recorded.

Time frame: 6 weeks post-procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.